Comparative Efficacy, Safety, PK, and Immunogenicity Study
NCT ID: NCT05853354
Last Updated: 2024-04-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE3
Total Enrollment
392 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-04-05
Study Completion Date
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture
NCT05060406
Postmenopausal Osteoporosis
UNKNOWN
PHASE3
A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection
NCT06095427
Healthy
COMPLETED
PHASE1
A Study to Evaluate LY06006 and Prolia in Healthy Adults
NCT04973722
Healthy Adults
UNKNOWN
PHASE1
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
NCT04664959
Postmenopausal Osteoporosis
COMPLETED
PHASE3
A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.
NCT05338086
Postmenopausal Women With Osteoporosis
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a randomized, double-blind, parallel-group, active-controlled, comparative study (Main Period) with a Transition Period to compare the efficacy, PD, safety, PK, and immunogenicity of LY06006 and EU-Prolia among female participants with postmenopausal osteoporosis.
Participants will go through a Screening Period within 35 days prior to first dosing. After signing the informed consent form (ICF), participants will be screened for age, menopausal status, and vitamin D levels, in addition to other inclusion/exclusion criteria. Participants will also undergo a screening DXA examination. Eligibility is based on the absolute value consistent with a T-score ≤ -2.5 and ≥ -4.0 at the lumbar spine.
Main Period Upon completing all screening assessments and meeting all eligibility criteria, participants will enter the Main Period of the study. The Main Period will last 12 months where participants will be randomized in a 1:1 ratio to receive either a dose (60 mg/1 mL) of LY06006 or EU-Prolia subcutaneously at the Baseline Visit (Day 1) and Month 6. All participants will receive daily supplements of elemental calcium (at least 1000 mg) and vitamin D (at least 400 IU). Study visits will occur at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12.
Follow-up BMD assessment will be done at Months 6 and 12. Blood sampling for PD, safety, PK, and immunogenicity will be done at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12.
Transition Period The Transition Period will be conducted in all participants who completed the Main Period of the study. At Month 12, participants who received EU-Prolia in the Main Period will be re-randomized in a 1:1 ratio to either be transitioned to receive a dose of LY06006 or continue on EU-Prolia subcutaneously. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the interactive response technology (IRT) system to maintain the blind of treatment assignment.
Blood sampling for PD, safety, PK, and immunogenicity will be done at Months 15 (PK and immunogenicity only) and 18. End of study (EoS) assessments will be performed at Month 18 or at the time of early discontinuation or withdrawal of the participant. The duration of the clinical phase for participants from the Screening Period until the EoS Visit is approximately 19 months (up to 5 weeks of Screening Period, 12 months of Main Period, and 6 months of Transition Period).
Participants will go through a Screening Period within 35 days prior to first dosing. After signing the informed consent form (ICF), participants will be screened for age, menopausal status, and vitamin D levels, in addition to other inclusion/exclusion criteria. Participants will also undergo a screening DXA examination. Eligibility is based on the absolute value consistent with a T-score ≤ -2.5 and ≥ -4.0 at the lumbar spine.
Main Period Upon completing all screening assessments and meeting all eligibility criteria, participants will enter the Main Period of the study. The Main Period will last 12 months where participants will be randomized in a 1:1 ratio to receive either a dose (60 mg/1 mL) of LY06006 or EU-Prolia subcutaneously at the Baseline Visit (Day 1) and Month 6. All participants will receive daily supplements of elemental calcium (at least 1000 mg) and vitamin D (at least 400 IU). Study visits will occur at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12.
Follow-up BMD assessment will be done at Months 6 and 12. Blood sampling for PD, safety, PK, and immunogenicity will be done at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12.
Transition Period The Transition Period will be conducted in all participants who completed the Main Period of the study. At Month 12, participants who received EU-Prolia in the Main Period will be re-randomized in a 1:1 ratio to either be transitioned to receive a dose of LY06006 or continue on EU-Prolia subcutaneously. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the interactive response technology (IRT) system to maintain the blind of treatment assignment.
Blood sampling for PD, safety, PK, and immunogenicity will be done at Months 15 (PK and immunogenicity only) and 18. End of study (EoS) assessments will be performed at Month 18 or at the time of early discontinuation or withdrawal of the participant. The duration of the clinical phase for participants from the Screening Period until the EoS Visit is approximately 19 months (up to 5 weeks of Screening Period, 12 months of Main Period, and 6 months of Transition Period).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Osteoporosis, Postmenopausal
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
This is a randomized, double-blind, parallel-group, active-controlled, comparative study (Main Period) with a Transition Period to compare the efficacy, PD, safety, PK and immunogenicity of LY06006 and EU-Prolia among female participants with postmenopausal osteoporosis.
Primary Study Purpose
OTHER
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Upon enrollment, each participant will receive a unique participant identification number.Participant numbers must not be re-used for any other participants.
Prior to dosing in the Transition Period and to maintain the blind throughout the study, participants will be re-randomized and receive a second randomization number. Participants randomized to receive EU-Prolia in the Main Period will be re-randomized to receive either LY06006 or continue to receive EU-Prolia. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the IRT system to maintain the blind of treatment assignment.
Prior to dosing in the Transition Period and to maintain the blind throughout the study, participants will be re-randomized and receive a second randomization number. Participants randomized to receive EU-Prolia in the Main Period will be re-randomized to receive either LY06006 or continue to receive EU-Prolia. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the IRT system to maintain the blind of treatment assignment.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY06006
to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.
Group Type
EXPERIMENTAL
Denosumab
Intervention Type
BIOLOGICAL
Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
EU Prolia
to be administered 2 doses to the patients at the main treatment period and 1 dose at the transition period.
Group Type
ACTIVE_COMPARATOR
Denosumab
Intervention Type
BIOLOGICAL
Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Denosumab
Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age
1. Participant is ≥ 60 to ≤ 90 years of age inclusive, at the time of signing the informed consent.
Type of Participant and Disease Characteristics
2. Participant is an ambulatory postmenopausal woman (defined as lack of menstrual period for at least 12 months prior to Screening Visit, for which there is no other obvious pathological or physiological cause).
* Serum FSH test can be done at the Screening Visit in case of uncertainty.
* Female participants who underwent bilateral oophorectomy (with or without hysterectomy) at least 6 weeks prior to the Screening Period are eligible to participate.
3. Participant is diagnosed with osteoporosis, with absolute BMD consistent with a T-score of ≤ -2.5 and ≥ -4.0 at the lumbar spine (L1-L4 region) as measured by DXA at the Screening Visit.
4. Participant has at least two lumbar vertebrae in L1-L4 region and one hip evaluable by DXA for BMD measurement at the Screening Visit.
Weight 5. Participant has body weight ≥ 50 kg and ≤ 90 kg at Screening. Informed Consent 6. Participant is able to read and understand, and willing to provide signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
\-
1. Participant is ≥ 60 to ≤ 90 years of age inclusive, at the time of signing the informed consent.
Type of Participant and Disease Characteristics
2. Participant is an ambulatory postmenopausal woman (defined as lack of menstrual period for at least 12 months prior to Screening Visit, for which there is no other obvious pathological or physiological cause).
* Serum FSH test can be done at the Screening Visit in case of uncertainty.
* Female participants who underwent bilateral oophorectomy (with or without hysterectomy) at least 6 weeks prior to the Screening Period are eligible to participate.
3. Participant is diagnosed with osteoporosis, with absolute BMD consistent with a T-score of ≤ -2.5 and ≥ -4.0 at the lumbar spine (L1-L4 region) as measured by DXA at the Screening Visit.
4. Participant has at least two lumbar vertebrae in L1-L4 region and one hip evaluable by DXA for BMD measurement at the Screening Visit.
Weight 5. Participant has body weight ≥ 50 kg and ≤ 90 kg at Screening. Informed Consent 6. Participant is able to read and understand, and willing to provide signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
\-
Exclusion Criteria
Medical Conditions
1. Participant has a history and/or presence of any severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray at Screening Visit.
2. Participant has a history and/or presence of hip fracture.
3. Participant has a history and/or presence of atypical femur fracture.
4. Participant presents with any active healing fracture, per assessment of the Investigator.
5. Participant has a history of bilateral hip replacement (unilateral is allowed if the other hip is evaluable by DXA).
6. Participant has history and/or presence of osteonecrosis of the external auditory canal.
7. Evidence of any of the following conditions which may affect BMD or interfere with the interpretation of the findings:
1. Participant has a history of bone disease e.g., osteomalacia, osteopetrosis, Paget's disease, or osteogenesis imperfecta.
2. Participant has a history of metabolic or other endocrinologic diseases such as Cushing's disease, hyperprolactinemia, hypopituitarism, acromegaly, malabsorption syndrome (or any gastrointestinal disorders associated with malabsorption, e.g., Crohn's disease and chronic pancreatitis).
3. Participant has a history of chronic inflammatory diseases, obvious sclerosis, osteophytosis, severe scoliosis, or other degenerative changes due to other co-morbidities.
4. Participant has a history or current hyperparathyroidism or hypoparathyroidism. Note: Mild non-clinically significant secondary hyperparathyroidism may be acceptable upon discussion with the Medical Monitor.
5. Participant has current uncontrolled hyperthyroidism or hypothyroidism. Note: Participants with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following criteria:
* If TSH level is within normal range, the participant is eligible.
* If TSH level is elevated (\> 5.5 μIU/mL and ≤ 10.0 μIU/mL) and serum free T4 is within normal range, the participant is eligible. If TSH is below the lower level of normal, the participant should be excluded.
6. Participant has other disease conditions where there is bone/joint involvement (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, multiple myeloma, achondroplasia, bone metastases, renal osteodystrophy, osteomyelitis).
8. Participant has hypocalcemia (defined as albumin adjusted serum calcium level \< 2.0 mmol/L \[8.0 mg/dL\] Grade 2 per Common Terminology Criteria for Adverse Events version 5.0) or hypercalcemia (defined as albumin adjusted serum calcium levels \> 2.62 mmol/L \[10.50 mg/dL\]).
9. Participant has vitamin D deficiency (defined as 25-hydroxy vitamin D level \< 20 ng/mL \[\< 50 nmol/L\]).
Note: Oral replenishment of vitamin D is permitted at the discretion of the Investigator and in accordance with local standard of care during the Screening Period. Participants can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25-hydroxy vitamin D level ≥ 20 ng/mL (≥ 50 nmol/L).
10. Participant has any malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.
11. Participant has known history of liver cirrhosis.
12. Participant has known history of hepatitis B, hepatitis C, or HIV infection, or an active infection including, but not limited to SARS-CoV-2, tests positive for hepatitis B (positive HBsAg, positive anti-HBc with negative anti-HBs), hepatitis C (hepatitis C antibody), or HIV antibody during the Screening Period.
13. Participant has oral or dental conditions:
1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.
2. Active dental or jaw condition which requires oral surgery.
3. Invasive dental procedure planned during the study or within the past 6 months (e.g., tooth extraction, dental implants, oral surgery).
4. Non-healed dental or oral surgery.
5. Active periodontal disease.
6. Poor oral hygiene.
14. Participant has a history of major surgery within 8 weeks prior to the Screening Period or planned, anticipated major surgery during the study.
15. Participant has a history and/or presence of significant cardiac disease or ECG abnormalities indicating significant risk for participating in the study as judged by the Investigator.
Prior/Concomitant Therapy
16. Participant shows contraindications to denosumab therapy (e.g., hypocalcemia), or calcium or vitamin D supplementation before starting study intervention administration.
17. Participant requires ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements).
18. Use of any of the below medications that can affect BMD:
l. Denosumab used at any time prior to Screening Visit.
1. Oral bisphosphonates at any dose for osteoporosis treatment:
* Used for \> 3 years cumulatively at Screening Visit.
* At any dose used within 1 year prior to Screening Visit (if ≤ 3 years of use cumulatively).
2. Intravenous bisphosphonate at any dose within 5 years prior to Screening Visit.
3. PTH or PTH analogues at any dose within 2 years prior to Screening Visit.
4. Systemic HRT (oral or transdermal estrogen), SERMs, tibolone, aromatase inhibitors, or androgens at any dose within 1 year prior to Screening Visit.
Note: Exceptionally, non-systemic vaginal estrogen treatment is permitted.
5. Calcitonin, or its derivatives, and calcimimetics (such as cinacalcet or etelcalcetide) at any dose within 12 months prior to Screening Visit.
6. Calcitriol, alfacalcidol, or eldecalcitol within 3 months of the Screening Visit.
7. Fluoride or strontium at any dose at any time prior to Screening Visit.
8. Romosozumab or cathepsin K inhibitors received at any time prior to Screening Visit.
9. Systemic glucocorticoids (≥ 5 mg prednisone or equivalent per day for more than 10 days or cumulative ≥ 50 mg) within 3 months prior to Screening Visit.
10. Other bone active drugs including anticonvulsants (except benzodiazepines, gabapentin, and pregabalin), heparin (including low molecular weight heparins), vitamin K (supplementation or therapeutic dose), vitamin K antagonists (e.g., warfarin, acenocumarol), emtricitabine, tenofovir, adefovir, systemic ketoconazole, adrenocorticotropic hormone, lithium, protease inhibitors, gonadotropin-releasing hormone agonist, aluminum, barbiturate, methotrexate, chemotherapeutic agents, cyclosporine, tacrolimus, or anabolic steroids at any dose within 3 months prior to Screening Visit. Prior/Concurrent Clinical Study Experience
19. Participant is receiving or has received another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study intervention administration in this study. Diagnostic Assessments
20. Participant has DXA measurements where:
1. Height, weight, or girth measurements may preclude accurate DXA measurements in the Investigator's opinion.
2. BMD absolute value is consistent with a T-score \< -4.0 at the total hip or femoral neck.
21. Participant has severe renal impairment (defined as participant in dialysis or with an eGFR \< 30 mL/min per MDRD formula).
22. Participant has inadequate hepatic function (ALT and/or AST ≥ 2 × ULN).
23. Participant presents with clinically significant leukopenia, neutropenia, or anemia as judged by the Investigator.
24. Participant has a known intolerance to calcium or vitamin D supplements.
25. Participant has a history of prescription drug abuse or any illicit drug use within 6 months prior to Screening Visit.
26. Participant has a history of alcohol abuse (defined as consuming more than 3 drinks on any day or more than 7 drinks per week) according to medical history within 6 months prior to Screening Visit.
27. Participant is a smoker or has used nicotine and nicotine-containing products within 12 months of Screening Visit.
28. Participant has a known sensitivity to mammalian cell-derived drug products.
29. Participant is immunosuppressed for any reason.
30. Participant has any other conditions including clinically significant medical conditions/disorders/diseases, psychiatric status, or laboratory abnormalities that in the opinion of the Investigator might interfere with the participant's ability to participate in the study, would pose a risk to the participant's safety, or interfere with the study evaluation, procedure, or completion.
1. Participant has a history and/or presence of any severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray at Screening Visit.
2. Participant has a history and/or presence of hip fracture.
3. Participant has a history and/or presence of atypical femur fracture.
4. Participant presents with any active healing fracture, per assessment of the Investigator.
5. Participant has a history of bilateral hip replacement (unilateral is allowed if the other hip is evaluable by DXA).
6. Participant has history and/or presence of osteonecrosis of the external auditory canal.
7. Evidence of any of the following conditions which may affect BMD or interfere with the interpretation of the findings:
1. Participant has a history of bone disease e.g., osteomalacia, osteopetrosis, Paget's disease, or osteogenesis imperfecta.
2. Participant has a history of metabolic or other endocrinologic diseases such as Cushing's disease, hyperprolactinemia, hypopituitarism, acromegaly, malabsorption syndrome (or any gastrointestinal disorders associated with malabsorption, e.g., Crohn's disease and chronic pancreatitis).
3. Participant has a history of chronic inflammatory diseases, obvious sclerosis, osteophytosis, severe scoliosis, or other degenerative changes due to other co-morbidities.
4. Participant has a history or current hyperparathyroidism or hypoparathyroidism. Note: Mild non-clinically significant secondary hyperparathyroidism may be acceptable upon discussion with the Medical Monitor.
5. Participant has current uncontrolled hyperthyroidism or hypothyroidism. Note: Participants with hypothyroidism who are on stable thyroid hormone replacement therapy may be allowed per the following criteria:
* If TSH level is within normal range, the participant is eligible.
* If TSH level is elevated (\> 5.5 μIU/mL and ≤ 10.0 μIU/mL) and serum free T4 is within normal range, the participant is eligible. If TSH is below the lower level of normal, the participant should be excluded.
6. Participant has other disease conditions where there is bone/joint involvement (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, multiple myeloma, achondroplasia, bone metastases, renal osteodystrophy, osteomyelitis).
8. Participant has hypocalcemia (defined as albumin adjusted serum calcium level \< 2.0 mmol/L \[8.0 mg/dL\] Grade 2 per Common Terminology Criteria for Adverse Events version 5.0) or hypercalcemia (defined as albumin adjusted serum calcium levels \> 2.62 mmol/L \[10.50 mg/dL\]).
9. Participant has vitamin D deficiency (defined as 25-hydroxy vitamin D level \< 20 ng/mL \[\< 50 nmol/L\]).
Note: Oral replenishment of vitamin D is permitted at the discretion of the Investigator and in accordance with local standard of care during the Screening Period. Participants can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25-hydroxy vitamin D level ≥ 20 ng/mL (≥ 50 nmol/L).
10. Participant has any malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.
11. Participant has known history of liver cirrhosis.
12. Participant has known history of hepatitis B, hepatitis C, or HIV infection, or an active infection including, but not limited to SARS-CoV-2, tests positive for hepatitis B (positive HBsAg, positive anti-HBc with negative anti-HBs), hepatitis C (hepatitis C antibody), or HIV antibody during the Screening Period.
13. Participant has oral or dental conditions:
1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.
2. Active dental or jaw condition which requires oral surgery.
3. Invasive dental procedure planned during the study or within the past 6 months (e.g., tooth extraction, dental implants, oral surgery).
4. Non-healed dental or oral surgery.
5. Active periodontal disease.
6. Poor oral hygiene.
14. Participant has a history of major surgery within 8 weeks prior to the Screening Period or planned, anticipated major surgery during the study.
15. Participant has a history and/or presence of significant cardiac disease or ECG abnormalities indicating significant risk for participating in the study as judged by the Investigator.
Prior/Concomitant Therapy
16. Participant shows contraindications to denosumab therapy (e.g., hypocalcemia), or calcium or vitamin D supplementation before starting study intervention administration.
17. Participant requires ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements).
18. Use of any of the below medications that can affect BMD:
l. Denosumab used at any time prior to Screening Visit.
1. Oral bisphosphonates at any dose for osteoporosis treatment:
* Used for \> 3 years cumulatively at Screening Visit.
* At any dose used within 1 year prior to Screening Visit (if ≤ 3 years of use cumulatively).
2. Intravenous bisphosphonate at any dose within 5 years prior to Screening Visit.
3. PTH or PTH analogues at any dose within 2 years prior to Screening Visit.
4. Systemic HRT (oral or transdermal estrogen), SERMs, tibolone, aromatase inhibitors, or androgens at any dose within 1 year prior to Screening Visit.
Note: Exceptionally, non-systemic vaginal estrogen treatment is permitted.
5. Calcitonin, or its derivatives, and calcimimetics (such as cinacalcet or etelcalcetide) at any dose within 12 months prior to Screening Visit.
6. Calcitriol, alfacalcidol, or eldecalcitol within 3 months of the Screening Visit.
7. Fluoride or strontium at any dose at any time prior to Screening Visit.
8. Romosozumab or cathepsin K inhibitors received at any time prior to Screening Visit.
9. Systemic glucocorticoids (≥ 5 mg prednisone or equivalent per day for more than 10 days or cumulative ≥ 50 mg) within 3 months prior to Screening Visit.
10. Other bone active drugs including anticonvulsants (except benzodiazepines, gabapentin, and pregabalin), heparin (including low molecular weight heparins), vitamin K (supplementation or therapeutic dose), vitamin K antagonists (e.g., warfarin, acenocumarol), emtricitabine, tenofovir, adefovir, systemic ketoconazole, adrenocorticotropic hormone, lithium, protease inhibitors, gonadotropin-releasing hormone agonist, aluminum, barbiturate, methotrexate, chemotherapeutic agents, cyclosporine, tacrolimus, or anabolic steroids at any dose within 3 months prior to Screening Visit. Prior/Concurrent Clinical Study Experience
19. Participant is receiving or has received another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study intervention administration in this study. Diagnostic Assessments
20. Participant has DXA measurements where:
1. Height, weight, or girth measurements may preclude accurate DXA measurements in the Investigator's opinion.
2. BMD absolute value is consistent with a T-score \< -4.0 at the total hip or femoral neck.
21. Participant has severe renal impairment (defined as participant in dialysis or with an eGFR \< 30 mL/min per MDRD formula).
22. Participant has inadequate hepatic function (ALT and/or AST ≥ 2 × ULN).
23. Participant presents with clinically significant leukopenia, neutropenia, or anemia as judged by the Investigator.
24. Participant has a known intolerance to calcium or vitamin D supplements.
25. Participant has a history of prescription drug abuse or any illicit drug use within 6 months prior to Screening Visit.
26. Participant has a history of alcohol abuse (defined as consuming more than 3 drinks on any day or more than 7 drinks per week) according to medical history within 6 months prior to Screening Visit.
27. Participant is a smoker or has used nicotine and nicotine-containing products within 12 months of Screening Visit.
28. Participant has a known sensitivity to mammalian cell-derived drug products.
29. Participant is immunosuppressed for any reason.
30. Participant has any other conditions including clinically significant medical conditions/disorders/diseases, psychiatric status, or laboratory abnormalities that in the opinion of the Investigator might interfere with the participant's ability to participate in the study, would pose a risk to the participant's safety, or interfere with the study evaluation, procedure, or completion.
Minimum Eligible Age
60 Years
Maximum Eligible Age
90 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Luye Pharma Group Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joe Tai
Role: STUDY_CHAIR
Luye Pharma Group Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trials Management Services, LLC
Thousand Oaks, California, United States
Site Status
Indago Research and Health Center, Inc.
Hialeah, Florida, United States
Site Status
Valley Institute of Research
Fort Worth, Texas, United States
Site Status
MHAT Dr. Atanas Dafovski AD
Kardzhali, , Bulgaria
Site Status
Medical Centre Leo Clinic EOOD
Plovdiv, , Bulgaria
Site Status
Diagnostic-consultative center Ascendent EOOD
Sofia, , Bulgaria
Site Status
Medical Center Leo Clinic EOOD
Varna, , Bulgaria
Site Status
CCR Brno s.r.o.
Brno, , Czechia
Site Status
Synexus Prague
Prague, , Czechia
Site Status
Gifu Prefectural General Med C.
Gifu, Gihu, Japan
Site Status
Asakawa Orthopedic Clinic
Chikugo, Hukuoka, Japan
Site Status
Obase Hospital - Orthopedics
Miyako-gun, Hukuoka, Japan
Site Status
Himeno Hospital
Yame-gun, Hukuoka, Japan
Site Status
Marunouchi Hospital
Matsumoto-shi, Nagano, Japan
Site Status
Nemoto Geka SeikeiGeka
Fujimi, Saitama, Japan
Site Status
Kobayakawa Orthopedic Rheumatologic
Fukuroi, Shizuoka, Japan
Site Status
Med Teda Ooimachi Orthopaedic
Shinagawa-ku, Tôkyô, Japan
Site Status
Koenji Orthopedic Surgery
Shinagawa-ku, Tôkyô, Japan
Site Status
Shimonoseki City Hospital
Shimonoseki, Yamaguchi, Japan
Site Status
Nakamura Hospital
Beppu, Ôita, Japan
Site Status
Centrum Medyczne Pratia Poznan
Skórzewo, Greater Poland Voivodeship, Poland
Site Status
Centrum Medyczne Pratia Poznan
Skórzewo, Greater Poland Voivodeship, Poland
Site Status
Synexus Polska Sp. z o.o.
Katowice, Silesian Voivodeship, Poland
Site Status
Centrum Medyczne Pratia Czestochowa
Częstochowa, , Poland
Site Status
Synexus Polska Sp. z o.o.
Częstochowa, , Poland
Site Status
Synexus Polska Sp. z o.o.
Gdansk, , Poland
Site Status
Centrum Medyczne Pratia Gdynia
Gdynia, , Poland
Site Status
Pratia Jelenia Gora
Jelenia Góra, , Poland
Site Status
Centrum Medyczne Pratia Katowice
Katowice, , Poland
Site Status
Pratia MCM Krakow
Krakow, , Poland
Site Status
Krakowskie Centrum Medyczne Sp.z o.o.
Krakow, , Poland
Site Status
Synexus Polska Sp. z. o.o.
Lodz, , Poland
Site Status
Centrum Medyczne AMED Oddzial w Lodzi
Lodz, , Poland
Site Status
Synexus Polska Sp. z o.o.
Poznan, , Poland
Site Status
FutureMeds Warszawa Centrum
Warsaw, , Poland
Site Status
Synexus Polska Sp. z o.o.
Warsaw, , Poland
Site Status
Centrum Medyczne AMED
Warsaw, , Poland
Site Status
Synexus Polska Sp. z o.o.
Wroclaw, , Poland
Site Status
FutureMeds Sp. z o.o.
Wroclaw, , Poland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Bulgaria
Czechia
Japan
Poland
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IND 138591
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-002312-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
LY06006/MRCT-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Evaluate the Denosumab in Healthy Adults
NCT03427853
UNKNOWN
PHASE1
A Study of LY2541546 in Women With Low Bone Mineral Density
NCT01144377
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture
NCT05352516
COMPLETED
PHASE3
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
NCT06804590
RECRUITING
PHASE3
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
NCT01575834
COMPLETED
PHASE3
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
NCT03974100
COMPLETED
PHASE3
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153
RECRUITING
PHASE4
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
NCT01668589
COMPLETED
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
NCT05067335
COMPLETED
PHASE3
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
NCT02732210
COMPLETED
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
NCT05345691
COMPLETED
PHASE3
Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers
NCT05245669
COMPLETED
PHASE1
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
NCT01495000
COMPLETED
PHASE3
Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
NCT05419427
UNKNOWN
PHASE3
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
NCT05405725
UNKNOWN
PHASE3
Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis
NCT00532545
COMPLETED
PHASE4
A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
NCT02157948
COMPLETED
PHASE3
Denosumab vs Zoledronate After Lumbar Fusion
NCT05638399
UNKNOWN
PHASE3
Risedronate in Osteopenic Postmenopausal Women
NCT00345644
COMPLETED
PHASE3
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
NCT00680953
COMPLETED
PHASE3
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT06938152
RECRUITING
PHASE4
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
NCT07062978
RECRUITING
PHASE3
Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
NCT04621318
COMPLETED
PHASE1
Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
NCT04940845
UNKNOWN
PHASE1
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
NCT06332014
RECRUITING
PHASE4